About Stelis Biopharma
Stelis Biopharma is a company based in Bengaluru (India) founded in 2013 by Sohang Chatterjee was acquired by Strides Pharma Science in September 2019. It operates as a B2B. Stelis Biopharma has raised $201.78 million across 8 funding rounds from investors including Strides Pharma Science, Accel and TPG. The company has 556 employees as of March 31, 2022. Stelis Biopharma offers products and services including Drug-Device Combinations, Sterile Injectables, Complex Biologics, and Soft Gelatin Capsules. Stelis Biopharma operates in a competitive market with competitors including KBI Biopharma, EirGenix, Aldevron, Arranta Bio and Ovagen, among others.
- Headquarter Bengaluru, India
- Employees 556 as on 31 Mar, 2022
- Founders Sohang Chatterjee
- Stage Minicorn
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Onesource Specialty Pharma Limited
- Date of Incorporation 12 Jun, 2007
- Jurisdiction Thane, Maharashtra, India
-
Annual Revenue
$16.44 M (USD)506.82as on Mar 31, 2022
-
Net Profit
-$27.97 M (USD)-91.31as on Mar 31, 2022
-
EBITDA
-$11.69 M (USD)-35.48as on Mar 31, 2022
-
Total Equity Funding
$201.78 M (USD)
in 8 rounds
-
Latest Funding Round
$125 M (USD), Series C
Mar 19, 2021
-
Investors
Strides Pharma Science
& 13 more
-
Employee Count
556
as on Mar 31, 2022
-
Acquired by
Strides Pharma Science
(Sep 20, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Stelis Biopharma
Stelis Biopharma offers a comprehensive portfolio of products and services, including Drug-Device Combinations, Sterile Injectables, Complex Biologics, and Soft Gelatin Capsules.
Assembly of drug-device products for pharmaceutical applications.
Development and manufacturing of complex injectable drugs.
Integrated solutions for biologics process and scale-up.
Production of high-quality capsules in various formats.
People of Stelis Biopharma
Unlock access to complete
Unlock access to complete
Funding Insights of Stelis Biopharma
Stelis Biopharma has successfully raised a total of $201.78M across 8 strategic funding rounds. The most recent funding activity was a Series C round of $125 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Stelis Biopharma
Stelis Biopharma has secured backing from 14 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Strides Pharma Science, Accel and TPG.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Fund of funds focused on pre-seed and seed-stage companies
|
Locked | Locked | Locked | |
|
Investment Firm
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Stelis Biopharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Stelis Biopharma
Investment portfolio details for Stelis Biopharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Stelis Biopharma
Detailed financials for Stelis Biopharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Stelis Biopharma Comparisons
Peer comparison for Stelis Biopharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Stelis Biopharma
Stelis Biopharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as KBI Biopharma, EirGenix, Aldevron, Arranta Bio and Ovagen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of protein formulation, process & cell line development, and cGMP services
|
|
| Locked | Locked | Locked |
Biologics development and manufacturing services are offered by EirGenix.
|
|
| Locked | Locked | Locked |
Developer and custom manufacturer of nucleic acids, proteins and antibodies for research, clinical and commercial applications
|
|
| Locked | Locked | Locked |
Developer of therapeutics for microbiome based diseases
|
|
| Locked | Locked | Locked |
Provider of germ-free and specific pathogen free production of eggs for vaccine and antibody manufacturing services
|
|
| Locked | Locked | Locked |
Vaccines and biologics are developed and manufactured by IDT Biologika.
|
Detailed competitors of Stelis Biopharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Stelis Biopharma
Complete news archive for Stelis Biopharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Stelis Biopharma
Stelis Biopharma was founded in 2013.
Stelis Biopharma is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
Stelis Biopharma is a funded company, having raised a total of $201.78M across 8 funding rounds to date.
As of Mar 31, 2022, the latest employee count at Stelis Biopharma is 556.
Annual revenue of Stelis Biopharma is $16.44M as on Mar 31, 2022.
OneSource is a CDMO specializing in pharmaceuticals and biologics, providing end-to-end services from concept to delivery. They operate state-of-the-art facilities in India, focusing on development, manufacturing, and compliance for various modalities like injectables and capsules. With expertise in regulatory approvals and tech transfer, they serve clients in the healthcare sector to transform ideas into market-ready products.
Stelis Biopharma's top competitors include KBI Biopharma, Aldevron and Ovagen.
Stelis Biopharma offers Drug-Device Combinations, Sterile Injectables, Complex Biologics, and Soft Gelatin Capsules.
Stelis Biopharma has 14 investors. Key investors include Strides Pharma Science, Accel, TPG, RouteOne, and Tenshi Life Sciences.
The valuation of Stelis Biopharma is $265.41M as of Mar 2021.